Northwestern University Human Resources

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1851-01-28

Employees: 5K

Market Cap: -

Website: https://www.venturecat.northwestern.edu

Clinical Trials

Brain Morphometry in OA Patients Treated With Duloxetine

Not Applicable

Completed

Conditions: Pain
Osteoarthritis

Interventions: Drug: Duloxetine
Drug: Placebo Oral Tablet

First Posted Date: 2016-09-16

Last Posted Date: 2017-03-07

Lead Sponsor: Northwestern University

Target Recruit Count: 21

Registration Number: NCT02903238

Locations: 🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States

Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2

Completed

Conditions: Recurrent Ovarian Carcinoma
Recurrent Fallopian Tube Carcinoma
Recurrent Primary Peritoneal Carcinoma

Interventions: Drug: Guadecitabine
Other: Laboratory Biomarker Analysis
Biological: Pembrolizumab

First Posted Date: 2016-09-15

Last Posted Date: 2024-02-20

Lead Sponsor: Northwestern University

Target Recruit Count: 45

Registration Number: NCT02901899

Locations: 🇺🇸
The University of Chicago Medicine, Chicago, Illinois, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Northwestern Lake Forest Hospital, Lake Forest, Illinois, United States

Health Effects of Mentoring

Not Applicable

Completed

Conditions: Cardiovascular Health

Interventions: Behavioral: Mentoring

First Posted Date: 2016-09-14

Last Posted Date: 2020-03-04

Lead Sponsor: Northwestern University

Target Recruit Count: 55

Registration Number: NCT02900638

Locations: 🇺🇸
Northwestern University, Evanston, Illinois, United States

Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer

Phase 2

Terminated

Conditions: Stage IV Inflammatory Breast Carcinoma
Recurrent Inflammatory Breast Carcinoma
Stage IV Breast Cancer
HER2/Neu Negative

Interventions: Biological: Ipilimumab
Other: Laboratory Biomarker Analysis
Biological: Nivolumab

First Posted Date: 2016-09-08

Last Posted Date: 2020-07-16

Lead Sponsor: Northwestern University

Target Recruit Count: 3

Registration Number: NCT02892734

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States

Vulvar Mucosal Specialty Clinic Chart Review

Terminated

Conditions: Lichen Sclerosus
Vulvar Disease
Vulvodynia
Lichen Planus

First Posted Date: 2016-08-26

Last Posted Date: 2020-10-09

Lead Sponsor: Northwestern University

Target Recruit Count: 719

Registration Number: NCT02881229

Locations: 🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States

Vulvar Scarring Grading Scale for Lichen Sclerosus

Terminated

Conditions: Lichen Sclerosus et Atrophicus
Lichen Sclerosus

First Posted Date: 2016-08-26

Last Posted Date: 2020-10-09

Lead Sponsor: Northwestern University

Target Recruit Count: 30

Registration Number: NCT02880904

Locations: 🇺🇸
Northwestern University Feinberg School of Medicine, Department of Dermatology, Chicago, Illinois, United States

Cocoa to Improve Walking Performance in Peripheral Artery Disease

Not Applicable

Completed

Conditions: Peripheral Artery Disease

Interventions: Drug: Cocoa
Drug: Placebo

First Posted Date: 2016-08-24

Last Posted Date: 2020-08-06

Lead Sponsor: Northwestern University

Target Recruit Count: 44

Registration Number: NCT02876887

Locations: 🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States

Anti-Inflammatory Agent in Sinusitis

Phase 2

Completed

Conditions: Nasal Polyps

Interventions: Drug: AZ compound
Drug: Intranasal corticosteroid
Other: Collection of Biological Specimens
Drug: Placebo

First Posted Date: 2016-08-22

Last Posted Date: 2022-05-25

Lead Sponsor: Northwestern University

Target Recruit Count: 43

Registration Number: NCT02874144

Reducing the Effects of Active Surveillance Stress, Uncertainty and Rumination Thru Engagement in Mindfulness Education

Not Applicable

Completed

Conditions: Prostate Cancer

Interventions: Behavioral: Health promotion

First Posted Date: 2016-08-18

Last Posted Date: 2023-03-13

Lead Sponsor: Northwestern University

Target Recruit Count: 225

Registration Number: NCT02871752

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

and more 1 locations

Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis

Phase 1

Withdrawn

Conditions: Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase
Primary Myelofibrosis

Interventions: Biological: Durvalumab
Other: Laboratory Biomarker Analysis

First Posted Date: 2016-08-18

Last Posted Date: 2019-08-20

Lead Sponsor: Northwestern University

Registration Number: NCT02871323

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy